PAOG - US Biopharma Tech Canna-Company Seeks Partnership in Israel
August 26 2020 - 12:58PM
InvestorsHub NewsWire
August 19, 2020 -- InvestorsHub NewsWire -- via Dope Magazine
PAO Group, Inc. (PAOG),
an Ohio-based biopharmaceutical tech company, has announced that
it’s aggressively seeking an international research
partnership—specifically, in Israel—to further its progress in
cannabis respiratory treatment development.
Israel, also known as “The Land of Milk and Honey,” has been
making tremendous strides in the medicinal cannabis sector,
particularly in research on the efficacy of cannabis in
treating COVID-19 side effects.
PAOG said in a press release,
“Israel is recognized as one of the leading cannabis research
centers in the world. Parallel to PAOG’s own research on its
proprietary cannabis extract for the treatment of
COVID-19, a study in Israel was
recently released with findings that [terpenes] in cannabis showed
efficacy in treating COVID-19.”
“Israel is recognized as one of the leading cannabis
research centers in the world. Parallel to PAOG’s own research on
its proprietary cannabis extract for the treatment of
COVID-19, a study in Israel was recently released with
findings that [terpenes] in cannabis showed efficacy in treating
COVID-19.”
PAOG offers its RespRX treatment for respiratory disease or
infection. This cannabis inhaler administers the company’s patented
CBD compound directly into the patient’s lungs.
But after obtaining and patenting the proprietary formulations
for the RespRX compound, PAOG hopes to partner with Israeli
researchers to improve the formula.
Before the COVID-19 pandemic hit, medical solutions to treat
both Chronic Obstructive Pulmonary Disease (COPD) and coronavirus
infections weren’t a priority for leading pharmaceutical
developers.
Now that the market for COVID-19 solutions has matured, the race
to develop a solution is underway. While pharmaceutical giants
including Glenmark Pharmaceuticals, GlaxoSmithKline, AstraZeneca,
and others scramble to uncover a solution, PAOG is also developing
a treatment.
PAOG told The Jerusalem Post,
“A paper on the results of the study was published and
well-received, given the potential impact on this large market. WHO
estimates 65 million people worldwide are afflicted with moderate
to severe COPD, and GlobalData forecasts that the COPD treatment
market will reach $14.1 billion by 2020.”
Treating existing illnesses that result in wheezing,
breathlessness and other lung problems is crucial with COVID-19’s
prevalence and potential to spread. Recent research
from MedRxiv highlights that
patients with these existing problems have a higher chance of
developing severe COVID-19 infections.
As COVID-19 poses an elevated threat to patients who already
have lung issues, PAOG’s Israeli partnership stands to perfect it’s
solution and secure its share of the market.
Source: https://dopemagazine.com/us-biopharma-tech-canna-company-seeks-partnership-in-israel/
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Apr 2023 to Apr 2024